Claims for Patent: 8,629,185

Summary for Patent: 8,629,185

Title:	7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Abstract:	The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.
Inventor(s):	Ambrus; Gyorgy F. (Santa Ana, CA), Karami; Kiomars (Aliso Viejo, CA), Wu; Ke (Irvine, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	12/951,780
Patent Claims:	1. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-eth- yl-hept-5-enamide having the structure ##STR00001## in crystalline form II. 2. A crystalline form of 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide having an X-ray powder diffraction pattern with peaks at (2.theta.): 3.60, 5.31, 7.09, 10.55, 12.24, 13.29, 14.55, 15.85, 17.60, 18.49, 19.00, 19.65, 21.10, 22.20, 22.69, 24.75 and 28.65. 3. The crystalline form of claim 1 having the X-ray diffraction pattern as shown in FIG. 2. 4. The crystalline form of claim 1 having an endothermic onset at about 70.9 .degree. C. and a peak at 74.5 .degree. C. in its differential scanning calorimetry profile. 5. The crystalline form of claim 1 having the DSC profile as shown in FIG. 1. 6. A pharmaceutical composition comprising a therapeutically effective amount of 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl- ]-N-ethyl-hept-5-enamide crystalline form II in an ophthalmically acceptable carrier therefore. 7. The crystalline form of claim 1 free of other crystalline forms.